International Journal of Drug Delivery最新文献_第3页

Formulation And In Vitro/In Vivo Evaluation Of Olmesartan Medoxomil Solid Dispersions Incorporated E/R Trilayer Matrix Tablets By Geomatrix 奥美沙坦美多沙米固体分散体含E/R三层基质片的制备及体外/体内评价

International Journal of Drug Delivery Pub Date : 2017-02-28 DOI: 10.5138/09750215.1948

M. Balakrishnaiah, V. Gupta

{"title":"Formulation And In Vitro/In Vivo Evaluation Of Olmesartan Medoxomil Solid Dispersions Incorporated E/R Trilayer Matrix Tablets By Geomatrix","authors":"M. Balakrishnaiah, V. Gupta","doi":"10.5138/09750215.1948","DOIUrl":"https://doi.org/10.5138/09750215.1948","url":null,"abstract":"An attempt has been made to develop and optimize an novel anti hypertensive trilayered controlled release matrix tablets incorporated with Olmesartan medoxomil solid dispersion prepared by direct compression and consisted of middle active layer with different grades of hydroxypropylmethylcellulose (HPMC), guar gum, ethyl cellulose. Upper and lower layers are prepared with Carnauba wax, guar gum and sodium CMC. The developed drug delivery system provided prolonged drug release rates over a period of 24 h. The release profile of the optimized formulation (HF14) was described by the Zero-order and Higuchi model. In-vivo bioavailability studies were carried out with the optimized formulation (HF14) and reference standard A fair correlation between the dissolution profile and bioavailability for the optimized formulation was observed. The results indicate that the approach used could lead to a successful development of a trilayer extended release formulation up to 24h. These results also demonstrated that the Olmesartan solid dispersion incorporated trilayer tablets shown more bioavailability because of its conversion from crystalline to amorphous form.","PeriodicalId":13912,"journal":{"name":"International Journal of Drug Delivery","volume":"18 1","pages":"125-133"},"PeriodicalIF":0.0,"publicationDate":"2017-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87221854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Structural designing of suppressors for autisms spectrum diseases using molecular dynamics sketch 基于分子动力学草图的自闭症谱系疾病抑制因子结构设计

International Journal of Drug Delivery Pub Date : 2017-02-28 DOI: 10.5138/09750215.1973

Bipin Nair, V. Bhaskaran, K. Arunjit

引用次数: 2

EPR effect based nanocarriers targeting for treatment of cancer 基于EPR效应的纳米载体靶向治疗癌症

International Journal of Drug Delivery Pub Date : 2017-02-28 DOI: 10.5138/09750215.1974

K. R. Gajbhiye, J. Gajbhiye

引用次数: 5

Development and validation of analytical methods for the simultaneous estimation of Nimorazole and Ofloxacin in tablet dosage form 片剂中尼莫唑和氧氟沙星含量同时测定方法的建立与验证

International Journal of Drug Delivery Pub Date : 2016-12-08 DOI: 10.5138/09750215.1792

A. Ghugare, L. Devhare, B. Hatwar

引用次数: 1

Enhancement of Solubility of Artemisinin and Curcumin by Co-Solvency Approach for Application in Parenteral Drug Delivery System 用共溶度法提高青蒿素和姜黄素在静脉给药系统中的溶解度

International Journal of Drug Delivery Pub Date : 2016-12-08 DOI: 10.5138/09750215.1868

V. Thakkar, R. Dhankecha, M. Gohel, P. Shah, T. Pandya, T. Gandhi

{"title":"Enhancement of Solubility of Artemisinin and Curcumin by Co-Solvency Approach for Application in Parenteral Drug Delivery System","authors":"V. Thakkar, R. Dhankecha, M. Gohel, P. Shah, T. Pandya, T. Gandhi","doi":"10.5138/09750215.1868","DOIUrl":"https://doi.org/10.5138/09750215.1868","url":null,"abstract":"The aim of present study was to enhance solubility of poorly soluble antimalarial drugs, Artemisinin and Curcumin by adopting Co-solvency approach and to develop parenteral aqueous injectable solution. Solubility enhancement of both drugs was achieved using co-solvency approach. The parenteral injection was prepared by using a ternary co-solvent system which comprised of benzyl alcohol, PEG 400 and tween 80 (as surfactant). Solubility of Artemisinin and Curcumin was found to be higher in benzyl alcohol and PEG 400. Co-solvent system comprising of benzyl alcohol, PEG 400 and tween 80 in volume fraction of 0.3, 0.9 and 0.2 respectively showed the minimum required solubility of Artemisinin (90 mg per ml) and Curcumin (180 mg per ml). The parenteral injectable formulation was characterized for pH, clarity, viscosity, osmolarity and sterility and the stated parameters were found in acceptable range. In-vitro erythrocyte toxicity study showed that intravenous administration of optimized formulation will be safe. In-vitro antimalarial assay indicated that efficacy of artemisinin and curcumin parenteral formulation was greater than quinine and combination of Artemether and Lumefantrine. Stability study of the optimized batch showed no change in physical and chemical characteristics. Based on study, one can conclude that Artemisinin and Curcumin can be successfully formulated as parenteral injectable formulation by co-solvency approach for the effective treatment of malarial infection","PeriodicalId":13912,"journal":{"name":"International Journal of Drug Delivery","volume":"9 1","pages":"77-88"},"PeriodicalIF":0.0,"publicationDate":"2016-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82128641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

In Vitro - In Vivo Evaluation Of E/R Trilayer Matrix Tablets Containing Solid Dispersion Of Atorvastatin 含阿托伐他汀固体分散体的E/R三层基质片的体内外评价

International Journal of Drug Delivery Pub Date : 2016-12-08 DOI: 10.5138/09750215.1947

A. Thirupathaiah, R. Sunder

{"title":"In Vitro - In Vivo Evaluation Of E/R Trilayer Matrix Tablets Containing Solid Dispersion Of Atorvastatin","authors":"A. Thirupathaiah, R. Sunder","doi":"10.5138/09750215.1947","DOIUrl":"https://doi.org/10.5138/09750215.1947","url":null,"abstract":"Investigation of in vitro/in vivo behaviour of extended release tablets containing solid dispersions of Atorvastatin is the focus of the present research work. Atorvastatin trilayer matrix tablets were prepared by direct compression method and consisted of middle active layer with different grades of hydroxypropylmethylcellulose (HPMC), ethyl cellulose and Carbopol 934P. Barrier layers are prepared with hydrophobic polymers carnauba wax and xanthan gum. Based on the evaluation parameters, drug dissolution profile and release order kinetics HF16 was found to be optimized formulation. The developed drug delivery system provided prolonged drug release rates over a period of 24 h. The release profile of the optimized formulation (HF16) was described by the Zero-order and best fitted to Higuchi model. FTIR confirmed that there was no chemical interaction between drug and excipients used in the formulation. . In vivo bioavailability studies were conducted for optimized formulation HF16 and reference standard. The optimized formulation of Atorvastatin trilayer matrix tablet was shown significant plasma concentration with extended release and maintained for 24 hrs with patient compliance by reducing the dosage frequency, when compared with reference standard.","PeriodicalId":13912,"journal":{"name":"International Journal of Drug Delivery","volume":"2 1","pages":"107-116"},"PeriodicalIF":0.0,"publicationDate":"2016-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82353541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Limonene and BEZ 235 inhibits growth of COLO-320 and HCT-116 colon cancer cells 柠檬烯和BEZ 235抑制结肠癌细胞COLO-320和HCT-116的生长

International Journal of Drug Delivery Pub Date : 2016-12-08 DOI: 10.5138/09750215.1919

Raja Ratna Reddy Yakkanti, P. C. Sekhar, K. Reddy, S. Ramamoorthy, S. Suresh, T. Lakshmi, M. Rajesh, C. Reddy

引用次数: 5

Effect of Sunlight, Moisture, Temperature and Ultraviolet Radiation on the Quality Control Parameters of Ciprofloxacin Tablet Formulation 光照、湿度、温度和紫外线辐射对环丙沙星片制剂质量控制参数的影响

International Journal of Drug Delivery Pub Date : 2016-12-08 DOI: 10.5138/09750215.1928

K. M. Ezealisiji, Angenlina Pepple, C. Stanley

{"title":"Effect of Sunlight, Moisture, Temperature and Ultraviolet Radiation on the Quality Control Parameters of Ciprofloxacin Tablet Formulation","authors":"K. M. Ezealisiji, Angenlina Pepple, C. Stanley","doi":"10.5138/09750215.1928","DOIUrl":"https://doi.org/10.5138/09750215.1928","url":null,"abstract":"This work assesses the stability and quality of Ciprofloxacin hydrochloride tablets after subjection to accelerated stability conditions of sunlight, temperature of 40±1 0 C, 75% relative humidity, and UV light of 365 nm for 4 hours each day. This study was performed at time zero and at 4-day intervals for a period of 45 days (that is, days 0, 4, 8, 12…40, 44) according to the International Conference on Harmonization (ICH) accelerated aging conditions and the results obtained were subjected to statistical analysis. The results showed that with increasing time there was a gradual reduction in the dissolution rate with the tablets exposed to all four storage conditions failing the test on day 44 where they had less than 80 % release of the label claim. For content of Ciprofloxacin Hydrochloride, only those tablets exposed to UV light passed the test for all 44 days as they had a minimum of 96.83 % content on the 44 th day. At day 0, all the tablets assayed passed this test, having a ciprofloxacin content of 99.43 %. For those tablets subjected to the other storage conditions including temperature of 40±1 0 C, 75 % relative humidity and sunlight, they had ciprofloxacin content of 70.22 %, 71.50 %, and 78.36 % respectively. The results further, indicated that the storage conditions used in the study had a greater impact on the dissolution behavior and content of the Ciprofloxacin tablets than they did on the physical stability (hardness, uniformity of weight, disintegration).","PeriodicalId":13912,"journal":{"name":"International Journal of Drug Delivery","volume":"106 1","pages":"99-106"},"PeriodicalIF":0.0,"publicationDate":"2016-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75617457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

Deep Percutaneous Penetration into Muscles and Joints: Update 深层经皮渗透到肌肉和关节:更新

International Journal of Drug Delivery Pub Date : 2014-01-01 DOI: 10.1007/978-1-4939-1289-6_13

Vladyslava Doktor, Christine M. Lee, H. Maibach

引用次数: 2

The emitted dose of drug from a valved holding chamber using five pressurized metered dose inhalers 使用5个加压计量吸入器从带阀的容纳室释放出的药物剂量

International Journal of Drug Delivery Pub Date : 2012-12-19 DOI: 10.5138/IJDD.V4I3.745

F. Berardino, A. Cesarani, Agostina Moles, O. Brenna

{"title":"The emitted dose of drug from a valved holding chamber using five pressurized metered dose inhalers","authors":"F. Berardino, A. Cesarani, Agostina Moles, O. Brenna","doi":"10.5138/IJDD.V4I3.745","DOIUrl":"https://doi.org/10.5138/IJDD.V4I3.745","url":null,"abstract":"Background. The dose available at the mouth from a pressurised metered-dose inhaler (pMDI) cannot stay the same if it is used with a valved holding chamber (VHC). A different aerosol drug delivery system is created when the pMDI is used with the VHC and therefore the dose delivered to the patients is no longer that released from the pMDI alone, but the one emitted by the new system. This study aims to verify the emitted dose of five pMDI drugs when used with a VHC. Methods. The emitted dose was expressed as the amount of drug within the respirable fraction available at the end of the VHC, i.e. the drug output (measured by high performance liquid chromatography) multiplied by the percentage of FDF determined using a laser diffraction analyser. Results. the emitted doses were drastically reduced in comparison with the nominal doses (Beclomethasone from 250 to 90.5 µg, Budesonide from 200 to 100 µg, Ciclesonide from 160 to 102 µg Fluticasone from 250 to 116 µg, Salbutamol from 100 to 54 µg). Conclusions. When pMDIs are employed with a VHC, the emitted dose drastically changes; it is more or less halved. In order to facilitate prescription by the physician, both the nominal and the emitted doses should be reported in the VHC package.","PeriodicalId":13912,"journal":{"name":"International Journal of Drug Delivery","volume":"16 1","pages":"336-340"},"PeriodicalIF":0.0,"publicationDate":"2012-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81124368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1